Oncometabolite Dioxygenase Inhibition Module

Oncology Metabolism Module oncometabolite_dioxygenase_inhibition 3 disorders Pathograph 8

A conserved mechanism module for the oncometabolite route to cancer: a lesion in a metabolic enzyme causes a small-molecule metabolite to accumulate to concentrations at which it competitively inhibits the 2-oxoglutarate-dependent dioxygenase superfamily, and the resulting loss of dioxygenase activity — not any energetic deficit — is what drives tumorigenesis. Two mechanistically opposite genetic routes converge on the same chemistry. Biallelic loss of a tricarboxylic-acid-cycle tumor suppressor (fumarate hydratase in hereditary leiomyomatosis and renal cell cancer; succinate dehydrogenase subunits in hereditary paraganglioma-pheochromocytoma and SDH-deficient gastrointestinal stromal tumor) causes its substrate to accumulate — fumarate or succinate respectively. A heterozygous neomorphic gain-of-function mutation in IDH1 or IDH2 instead creates a metabolite the cell does not normally make, R-2-hydroxyglutarate. All three are structural analogues of 2-oxoglutarate and all three act as competitive inhibitors at the shared 2-oxoglutarate site. The consequences split into two evidenced effector branches: stabilization of hypoxia-inducible factor through inhibition of the HIF prolyl hydroxylases, producing a pseudohypoxic, hypervascular tumor phenotype in normoxia; and inhibition of the TET 5-methylcytosine hydroxylases and the Jumonji-family histone demethylases, producing genome-wide DNA and histone hypermethylation with a differentiation block. A third, FH-specific branch is chemically distinct: fumarate covalently succinates cysteine residues on KEAP1, which is a modification rather than a competitive inhibition and activates NRF2 antioxidant signalling independently of HIF. This module is deliberately NOT a duplicate of deregulated_cellular_energetics, which models Warburg-type glycolytic reprogramming as a biosynthetic supply strategy; here the metabolic change is a signalling lesion whose targets are chromatin and the hypoxia response.

⚙

Pathophysiology Nodes

7 shared nodes are defined in this module.

◉

Cell Types

No cell types are annotated for this module.

⇄

Biological Processes

tricarboxylic acid cycle GO:0006099 DECREASED cellular response to decreased oxygen levels GO:0036294 INCREASED chromosomal 5-methylcytosine DNA demethylation pathway GO:0141166 DECREASED demethylation GO:0070988 DECREASED cellular response to oxidative stress GO:0034599 INCREASED

Notes

This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "oncometabolite_dioxygenase_ inhibition#Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases"). Substitutions a conforming entry makes at the trigger and accumulation nodes: FH loss / fumarate (hereditary leiomyomatosis and renal cell cancer); SDHA, SDHB, SDHC, SDHD or SDHAF2 loss / succinate in hereditary paraganglioma-pheochromocytoma, SDH-deficient GIST and Carney-Stratakis; IDH1 or IDH2 neomorphic mutation / R-2-hydroxyglutarate (glioma, acute myeloid leukaemia, chondrosarcoma, cholangiocarcinoma). Three things a conformer must not blur. (1) The genetic architecture differs between routes and only the TCA-enzyme route is a two-hit tumor suppressor mechanism — an FH or SDHx disorder should ALSO conform to germline_two_hit_tumor_predisposition, whereas the IDH route is a heterozygous neomorphic gain in which the wild-type allele is retained and must not be curated as needing a second hit. (2) The two effector branches are separately evidenced and a conformer should attach to the one it actually demonstrates; the relative contribution of the HIF branch is contested and is curated as competing mechanistic_hypotheses rather than settled. (3) The KEAP1-succination branch is chemically specific to fumarate — succinate and 2-hydroxyglutarate do not succinate cysteines — so an SDHx or IDH conformer must not attach there. Key conformance target (rate-limiting node): "oncometabolite_dioxygenase_inhibition#Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases".

Mechanistic Hypotheses

Pseudohypoxic HIF Activation as the Oncogenic Driver

hif_pseudohypoxia_driver CANONICAL Evidence: 1

Evidence balance 1 support

The long-standing reading: inhibition of the HIF prolyl hydroxylases and the resulting constitutive HIF transcriptional programme is what transforms the cell, which is why these tumors are hypervascular and why HIF-directed therapy was proposed for FH- and SDH-associated neoplasia.

Epigenetic Hypermethylation and Differentiation Block as the Oncogenic Driver

epigenetic_hypermethylation_driver ALTERNATIVE Evidence: 1

Evidence balance 1 support

The competing reading: the transforming event is inhibition of the TET and Jumonji demethylases, producing a hypermethylator phenotype that silences differentiation programmes. Support includes the correlation between severity of silencing and malignancy across SDHx genotypes, the same signature in IDH-mutant leukaemia where there is no TCA lesion at all, and pharmacological reversal by a hypomethylating agent.

KEAP1 Succination and NRF2 Dysregulation as the Oncogenic Driver (FH-Specific)

nrf2_succination_driver ALTERNATIVE Evidence: 1

Evidence balance 1 support

An FH-specific alternative in which the transforming event is covalent succination of KEAP1 and consequent constitutive NRF2 antioxidant signalling, not HIF stabilization. Mouse genetics is the strongest evidence: Fh1-associated renal cyst formation proceeds without HIF, and deleting Hif-1a makes cysts worse rather than better.

Discussions and Knowledge Gaps

Which branch downstream of dioxygenase inhibition actually drives tumorigenesis — pseudohypoxic HIF stabilization, epigenetic hypermethylation, or (for fumarate) KEAP1 succination and NRF2 activation?

CONTROVERSY OPEN controversy_hif_versus_epigenetic_driver

Attached to: Pseudohypoxic HIF Stabilization Impaired Demethylation and Genome-Wide Hypermethylation KEAP1 Succination and NRF2 Antioxidant Pathway Activation

This is not cosmetic: it decides what a conforming disorder should curate as its therapeutic rationale. If HIF is the driver, HIF-directed therapy is indicated and the hypervascularity is causal; if the epigenetic branch is the driver, hypomethylating agents are the rationale and HIF activation is a marker; if succination and NRF2 dominate in FH-deficient disease, then both of the other rationales are misdirected for that genotype specifically. The mouse genetics is the sharpest evidence against a simple HIF-driver model, because deleting Hif-1a in Fh1-deficient kidney exacerbated rather than prevented cyst formation. Curators should keep the branches separated as hypothesis groups on the relevant edges rather than asserting a single causal chain.

Proposed experiments: Branch-selective genetic rescue in each conforming genotype

Do the branch-assignment results obtained in mouse models and cultured cells hold in the human tumors of the corresponding hereditary syndromes?

HUMAN MODEL MISMATCH OPEN gap_human_model_fidelity_of_branch_evidence

Attached to: KEAP1 Succination and NRF2 Antioxidant Pathway Activation Oncometabolite-Driven Tumorigenesis with Differentiation Block

The two claims that most constrain therapeutic reasoning rest on non-human systems: HIF-independence of cyst formation comes from Fh1-deficient mice, and the decitabine reversal comes from cultured mouse chromaffin cells. The human evidence in this module is observational — hypermethylation clusters and HIF overexpression correlate with genotype in human tumors, but no human experiment separates the branches. A conforming human disorder entry should therefore not curate the branch assignment as established human mechanism, and should mark model-derived claims with evidence_source MODEL_ORGANISM or IN_VITRO rather than presenting them as human clinical findings.

↗

Used By Disorder Entries

Hereditary Leiomyomatosis and Renal Cell Cancer via Fumarate Accumulation → Oncometabolite Accumulation , Fumarate-Mediated Dioxygenase Inhibition → Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases , Pseudohypoxic HIF Stabilization in FH-Null Cells → Pseudohypoxic HIF Stabilization , KEAP1 Succination and NRF2 Activation → KEAP1 Succination and NRF2 Antioxidant Pathway Activation

Hereditary Pheochromocytoma-Paraganglioma Syndrome via Succinate Accumulation → Oncometabolite Accumulation , Succinate-Mediated Dioxygenase Inhibition → Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases , Pseudohypoxic HIF Stabilization in SDH-Deficient Cells → Pseudohypoxic HIF Stabilization , Hypermethylator Phenotype and Neuroendocrine Differentiation Block → Impaired Demethylation and Genome-Wide Hypermethylation

Pheochromocytoma and Paraganglioma via Succinate Dehydrogenase Complex Dysfunction → Metabolic Enzyme Lesion (TCA Tumor Suppressor Loss or IDH Neomorphic Gain) , Succinate Accumulation and Oncometabolite Signaling → Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases , DNA and Histone Hypermethylator Phenotype → Impaired Demethylation and Genome-Wide Hypermethylation , Pseudohypoxia and HIF Activation → Pseudohypoxic HIF Stabilization

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

Metabolic Enzyme Lesion (TCA Tumor Suppressor Loss or IDH Neomorphic Gain)

trigger

The initiating lesion, reached by two opposite genetic routes. In the tumor suppressor route, both alleles of a TCA-cycle enzyme gene are inactivated — fumarate hydratase in hereditary leiomyomatosis and renal cell cancer, or a succinate dehydrogenase subunit in hereditary paraganglioma-pheochromocytoma — typically a germline first hit plus somatic loss of the wild-type allele. In the oncogene route, a heterozygous missense mutation at IDH1 R132 or IDH2 R140/R172 confers a neomorphic activity while the wild-type allele is retained, so there is simultaneous partial loss of normal 2-oxoglutarate production and gain of a new product.

Used by disorders

Pheochromocytoma and Paraganglioma as Succinate Dehydrogenase Complex Dysfunction

Downstream

Oncometabolite Accumulation Loss of the enzyme that consumes the metabolite, or gain of an enzyme that makes a new one, raises intracellular concentration by orders of magnitude.

Oncometabolite Accumulation

amplifier

The metabolite immediately upstream of the disabled enzyme, or the neomorphic product, accumulates to concentrations far above physiological. Succinate accumulates when succinate dehydrogenase is inhibited; fumarate accumulates when fumarate hydratase is lost; R-2-hydroxyglutarate is produced de novo by mutant IDH. What unites them is structural: each is a close analogue of 2-oxoglutarate, the obligatory co-substrate of an entire dioxygenase superfamily, and each is present at concentrations sufficient to compete with it.

tricarboxylic acid cycle GO:0006099 DECREASED

Used by disorders

Hereditary Leiomyomatosis and Renal Cell Cancer as Fumarate Accumulation

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Succinate Accumulation

Downstream

Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases At the concentrations reached, the accumulated analogue occupies the 2-oxoglutarate site of dioxygenases and blocks catalysis.
KEAP1 Succination and NRF2 Antioxidant Pathway Activation Fumarate alone additionally reacts covalently with cysteine thiols, a chemically distinct route not shared by succinate or 2-hydroxyglutarate.

Competitive Inhibition of 2-Oxoglutarate-Dependent Dioxygenases

central effector

The rate-limiting, disorder-agnostic node this module exists to name. The accumulated oncometabolite occupies the same active-site space as 2-oxoglutarate and competitively inhibits the superfamily of enzymes that require it — the HIF prolyl hydroxylases, the TET family of 5-methylcytosine hydroxylases, and the Jumonji-domain histone demethylases, among others. Inhibition is not selective for one target, which is why a single metabolic lesion produces simultaneous hypoxia-response and chromatin phenotypes, and why the tumor phenotype cannot be explained by ATP deficiency.

Used by disorders

Hereditary Leiomyomatosis and Renal Cell Cancer as Fumarate-Mediated Dioxygenase Inhibition

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Succinate-Mediated Dioxygenase Inhibition

Pheochromocytoma and Paraganglioma as Succinate Accumulation and Oncometabolite Signaling

Downstream

Pseudohypoxic HIF Stabilization Inhibition of the HIF prolyl hydroxylases prevents hydroxylation-dependent VHL recognition, so HIF escapes degradation under normal oxygen tension.
Impaired Demethylation and Genome-Wide Hypermethylation Inhibition of the TET hydroxylases and Jumonji histone demethylases blocks the removal of methyl marks from DNA and histones.

Pseudohypoxic HIF Stabilization

effector

With the prolyl hydroxylases inhibited, HIF-alpha subunits are not hydroxylated, are not recognized by the VHL E3 ligase, and accumulate in normoxia. The cell therefore transcribes the hypoxia programme — angiogenic, glycolytic and invasion-associated target genes — while oxygen is adequate. This is the mechanistic explanation for why highly vascular tumors arise in these syndromes without any VHL mutation, and it is the point of convergence with von Hippel-Lindau disease, which reaches the same state from the opposite direction by losing the ligase instead of inhibiting the hydroxylase.

cellular response to decreased oxygen levels GO:0036294 INCREASED

Used by disorders

Hereditary Leiomyomatosis and Renal Cell Cancer as Pseudohypoxic HIF Stabilization in FH-Null Cells

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Pseudohypoxic HIF Stabilization in SDH-Deficient Cells

Pheochromocytoma and Paraganglioma as Pseudohypoxia and HIF Activation

Downstream

Oncometabolite-Driven Tumorigenesis with Differentiation Block Constitutive hypoxia-response transcription supports angiogenesis, glycolytic metabolism and invasive behaviour in the developing tumor.

Impaired Demethylation and Genome-Wide Hypermethylation

effector

Inhibition of the TET 5-methylcytosine hydroxylases and the Jumonji-family histone demethylases blocks the removal of methyl marks, so DNA and histone methylation accumulate genome-wide. In SDHx-mutated paraganglioma this produces a distinct hypermethylator cluster with downregulation of the genes that specify neuroendocrine differentiation; in IDH-mutant acute myeloid leukaemia the same chemistry produces a global hypermethylation signature with impaired haematopoietic differentiation. The severity tracks the genotype — epigenetic silencing is most marked in SDHB-mutated tumors, which are also the most malignant.

chromosomal 5-methylcytosine DNA demethylation pathway GO:0141166 DECREASED demethylation GO:0070988 DECREASED

Used by disorders

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Hypermethylator Phenotype and Neuroendocrine Differentiation Block

Pheochromocytoma and Paraganglioma as DNA and Histone Hypermethylator Phenotype

Downstream

Oncometabolite-Driven Tumorigenesis with Differentiation Block Hypermethylation silences differentiation programmes, locking cells in a progenitor-like, migration-competent state.

KEAP1 Succination and NRF2 Antioxidant Pathway Activation

adaptive escape

A branch specific to fumarate and chemically distinct from the rest of the module: fumarate reacts covalently with cysteine thiols to form S-(2-succinyl)cysteine, and succination of KEAP1 abrogates its ability to repress NRF2. The NRF2 antioxidant transcriptional programme is then constitutively active. Mouse genetics places this branch outside the HIF axis — Fh1-associated renal cyst formation proceeds independently of HIF — which is the principal reason the HIF branch cannot be assumed to be the sole oncogenic driver in FH-deficient disease.

cellular response to oxidative stress GO:0034599 INCREASED

Used by disorders

Hereditary Leiomyomatosis and Renal Cell Cancer as KEAP1 Succination and NRF2 Activation

Downstream

Oncometabolite-Driven Tumorigenesis with Differentiation Block Constitutive antioxidant signalling supports survival of cells carrying the metabolic lesion.

Oncometabolite-Driven Tumorigenesis with Differentiation Block

consequence

The convergent output: tumors that are characteristically hypervascular, metabolically reprogrammed, and blocked in differentiation, arising in the specific lineages each genotype affects — smooth muscle and renal tubular epithelium for FH, chromaffin and paraganglionic tissue for SDHx, glial and haematopoietic progenitors for IDH. Reversibility is part of the evidence for the mechanism: the migratory phenotype induced by succinate accumulation in SDH-deficient cells is reversed by a DNA hypomethylating agent, which would not be expected if the hypermethylation were a bystander mark.